{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T09:41:28Z","timestamp":1795081288198,"version":"4.10.2"},"reference-count":42,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T00:00:00Z","timestamp":1735862400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.eururo.2024.12.015","type":"journal-article","created":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T23:52:56Z","timestamp":1738194776000},"page":"672-682","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Final Overall Survival and Molecular Data Associated with Clinical Outcomes in Patients Receiving Ipatasertib and Abiraterone in the Phase 3 IPATential150 Trial"],"prefix":"10.1016","volume":"87","author":[{"given":"Johann S.","family":"de Bono","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malgorzata","family":"Nowicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Bracarda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cora N.","family":"Sternberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim N.","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Olmos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahneen","family":"Sandhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Massard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuaki","family":"Matsubara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nives Selak","family":"Bienz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Canter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Wongchenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Sweeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2024.12.015_b0005","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S1470-2045(18)30860-X","article-title":"Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Smith","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2024.12.015_b0010","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.12.015_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2016.08.018","article-title":"Predicting time from metastasis to overall survival in castration-resistant prostate cancer: results from SEARCH","volume":"15","author":"Moreira","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.eururo.2024.12.015_b0020","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/pcan.2016.17","article-title":"Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting","volume":"19","author":"Antonarakis","year":"2016","journal-title":"Prostate Cancer Prostat Dis"},{"key":"10.1016\/j.eururo.2024.12.015_b0025","doi-asserted-by":"crossref","first-page":"4492","DOI":"10.1172\/JCI128212","article-title":"Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer","volume":"129","author":"Labrecque","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1016\/j.eururo.2024.12.015_b0030","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/s41467-021-21615-4","article-title":"Inter- and intra-tumor heterogeneity of metastatic prostate cancer determined by digital spatial gene expression profiling","volume":"12","author":"Brady","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.eururo.2024.12.015_b0035","doi-asserted-by":"crossref","first-page":"55069","DOI":"10.18632\/oncotarget.10396","article-title":"Phenotypic and genetic heterogeneity of tumor tissue and circulating tumor cells in patients with metastatic castration-resistant prostate cancer: a report from the PETRUS prospective study","volume":"7","author":"Massard","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.eururo.2024.12.015_b0040","doi-asserted-by":"crossref","DOI":"10.1126\/science.abe1505","article-title":"Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets","volume":"376","author":"Tang","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.eururo.2024.12.015_b0045","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11010160","article-title":"Overview of the development and use of Akt inhibitors in prostate cancer","volume":"11","author":"Gasmi","year":"2021","journal-title":"J Clin Med."},{"key":"10.1016\/j.eururo.2024.12.015_b0050","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nrurol.2018.9","article-title":"Clinical implications of PTEN loss in prostate cancer","volume":"15","author":"Jamaspishvili","year":"2018","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.eururo.2024.12.015_b0055","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.eururo.2014.10.027","article-title":"PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate","volume":"67","author":"Ferraldeschi","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.12.015_b0060","article-title":"Real-world overall survival and treatment patterns by PTEN status in metastatic castration-resistant prostate cancer","volume":"8","author":"Gupta","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.eururo.2024.12.015_b0065","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1038\/modpathol.2011.207","article-title":"Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer","volume":"25","author":"Reid","year":"2012","journal-title":"Mod Pathol"},{"key":"10.1016\/j.eururo.2024.12.015_b0070","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ejca.2013.08.017","article-title":"The multiple layers of non-genetic regulation of PTEN tumour suppressor activity","volume":"50","author":"Correia","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eururo.2024.12.015_b0075","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/path.1929","article-title":"The PTEN gene in locally progressive prostate cancer is preferentially inactivated by bi-allelic gene deletion","volume":"208","author":"Verhagen","year":"2006","journal-title":"J Pathol"},{"key":"10.1016\/j.eururo.2024.12.015_b0080","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1038\/s41416-020-0834-6","article-title":"Emerging role of PTEN loss in evasion of the immune response to tumours","volume":"122","author":"Vidotto","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.eururo.2024.12.015_b0085","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1158\/1078-0432.CCR-18-0981","article-title":"Randomized phase II study evaluating Akt blockade with ipatasertib, in combination with abiraterone, in patients with metastatic prostate cancer with and without PTEN loss","volume":"25","author":"de Bono","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2024.12.015_b0090","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0140-6736(21)00580-8","article-title":"Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial","volume":"398","author":"Sweeney","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2024.12.015_b0095","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/modpathol.2016.88","article-title":"Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH","volume":"29","author":"Lotan","year":"2016","journal-title":"Mod Pathol"},{"issue":"Suppl","key":"10.1016\/j.eururo.2024.12.015_b0100","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1200\/JCO.2021.39.6_suppl.13","article-title":"PI3K\/AKT pathway biomarkers analysis from the phase III IPATential150 trial of ipatasertib plus abiraterone in metastatic castration resistant prostate cancer","volume":"396","author":"de Bono","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.12.015_b0105","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1158\/1078-0432.CCR-12-3072","article-title":"Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor models","volume":"19","author":"Lin","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2024.12.015_b0110","doi-asserted-by":"crossref","first-page":"8110","DOI":"10.1021\/jm301024w","article-title":"Discovery and preclinical pharmacology of a selective ATP-competitive Akt inhibitor (GDC-0068) for the treatment of human tumors","volume":"55","author":"Blake","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.eururo.2024.12.015_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2023.01.001","article-title":"Safety profile of ipatasertib plus abiraterone vs placebo plus abiraterone in metastatic castration-resistant prostate cancer","volume":"21","author":"Matsubara","year":"2023","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.eururo.2024.12.015_b0120","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00280-022-04488-2","article-title":"Characterization of exposure-response relationships of ipatasertib in patients with metastatic castration-resistant prostate cancer in the IPATential150 study","volume":"90","author":"Kotani","year":"2022","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.eururo.2024.12.015_b0125","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature08460","article-title":"Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1","volume":"462","author":"Barbie","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.eururo.2024.12.015_b0130","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.eururo.2024.12.015_b0135","doi-asserted-by":"crossref","first-page":"65566","DOI":"10.18632\/oncotarget.19217","article-title":"PTEN loss detection in prostate cancer: comparison of PTEN immunohistochemistry and PTEN FISH in a large retrospective prostatectomy cohort","volume":"8","author":"Lotan","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.eururo.2024.12.015_b0140","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/ng.370","article-title":"Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate","volume":"41","author":"Carver","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.eururo.2024.12.015_b0145","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/ng.371","article-title":"Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis","volume":"41","author":"King","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.eururo.2024.12.015_b0150","doi-asserted-by":"crossref","first-page":"7033","DOI":"10.1038\/s41467-021-26840-5","article-title":"Dynamic prostate cancer transcriptome analysis delineates the trajectory to disease progression","volume":"12","author":"Bolis","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.eururo.2024.12.015_b0155","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a030486","article-title":"DNA damage response in prostate cancer","volume":"9","author":"Schiewer","year":"2019","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.eururo.2024.12.015_b0160","first-page":"617","article-title":"MYC and prostate cancer. Genes","volume":"1","author":"Koh","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2024.12.015_b0165","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","article-title":"Capivasertib in hormone receptor-positive advanced breast cancer","volume":"388","author":"Turner","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.12.015_b0170","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1038\/modpathol.2014.70","article-title":"Heterogeneity and chronology of PTEN deletion and ERG fusion in prostate cancer","volume":"27","author":"Krohn","year":"2014","journal-title":"Mod Pathol"},{"key":"10.1016\/j.eururo.2024.12.015_b0175","doi-asserted-by":"crossref","first-page":"831","DOI":"10.2217\/bmm-2019-0141","article-title":"Identification of critical pathways and hub genes in TP53 mutation prostate cancer by bioinformatics analysis","volume":"13","author":"Sun","year":"2019","journal-title":"Biomark Med"},{"key":"10.1016\/j.eururo.2024.12.015_b0180","first-page":"1579","article-title":"TP53 gene mutations in prostate cancer progression","volume":"30","author":"Ecke","year":"2010","journal-title":"Anticancer Res"},{"key":"10.1016\/j.eururo.2024.12.015_b0185","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1158\/2159-8290.CD-17-0937","article-title":"Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer","volume":"8","author":"Annala","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.eururo.2024.12.015_b0190","article-title":"Comprehensive analysis of TP53 and SPOP mutations and their impact on survival in metastatic prostate cancer","volume":"12","author":"Zhou","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.eururo.2024.12.015_b0195","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.eururo.2018.11.045","article-title":"Compound genomic alterations of TP53, PTEN, and RB1 tumor suppressors in localized and metastatic prostate cancer","volume":"76","author":"Hamid","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.12.015_b0200","article-title":"Correlation of integrated ERG\/PTEN assessment with biochemical recurrence in prostate cancer","volume":"29","author":"Brady","year":"2021","journal-title":"Cancer Treat Res Commun"},{"key":"10.1016\/j.eururo.2024.12.015_b0205","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","article-title":"Targeting PI3K\/Akt signal transduction for cancer therapy","volume":"6","author":"He","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.eururo.2024.12.015_b0210","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/PPO.0000000000000217","article-title":"The role of next-generation sequencing in castration-resistant prostate cancer treatment","volume":"22","author":"Hovelson","year":"2016","journal-title":"Cancer J"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283824027714?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283824027714?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T04:00:58Z","timestamp":1788667258000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283824027714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0302283824027714"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2024.12.015","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Final Overall Survival and Molecular Data Associated with Clinical Outcomes in Patients Receiving Ipatasertib and Abiraterone in the Phase 3 IPATential150 Trial","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2024.12.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}